Navigation Links
£34M injection offers new hope for anti-cancer medicines

The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of the largest healthcare investment by a European private biotech company in over a year.

Patients with advanced cancer are already benefiting from the first of these new agents, and three more new agents will follow in the next 18-24 months.

Edinburgh based biopharmaceutical company, NuCana, has announced a new 34M investment to develop its portfolio of anti-cancer medicines based on ProTide technology.

ProTides is a platform developed by Professor Chris McGuigan and his team at Cardiff University's School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cancer cell resistance pathways that limit the efficacy of so many of today's anti-cancer drugs.

The funds will be used to advance and expand the clinical programme for NuCana's lead product, Acelarin, which has shown exceptional results in patients with a broad range of advanced and progressive cancers that were resistant to all conventional therapies.

Acelarin will be developed initially for patients with pancreatic, biliary, lung and ovarian cancers. In addition, the funding means the company plans to bring a second ProTide (NUC-3373) into the clinic later this year, with two further ProTides scheduled for 2015.

"It is very exciting to watch a new medicine emerge, from a theoretical idea, through chemical synthesis in our laboratory here in Cardiff and now as a new treatment for patients with cancer" according to Professor McGuigan, who developed the ProTide technology.

"This 34M investment is extremely satisfying and an endorsement of our work with NuCana. Over the last decade this represents the 14th largest private biotech round globally and the largest ever in the UK," he added.

The financing is led by a new investor, US based venture capital firm Sofinnova Ventures. The deal was completed by substantial investments from the largest shareholder, Paris based Sofinnova Partners, alongside other existing major investors Morningside Ventures, Alida Capital International and the Scottish Investment Bank.

NuCana has exclusive worldwide rights to the pioneering ProTide technology in cancer. This technology creates compounds that bypass key resistance mechanisms associated with anti-cancer drugs.

"We are delighted to be working with Chris McGuigan and the team in Cardiff. Over the years we have had a very constructive and productive collaboration with Cardiff University that is now bringing real benefits to patients," said Hugh S Griffith, the Co-Founder and CEO of NuCana.

Professor McGuigan added: "NuCana's ProTide platform has the potential to deliver to patients novel, first-in-class anti-cancer medicines. We are excited to be working with the company's experienced leadership team in the development programme.

"This investment is a real vote of confidence in our research and its application by NuCana. Together this brings real potential for developing new and powerful medicines to treat cancer."


Contact: Chris McGuigan
Cardiff University

Related biology news :

1. Toxic injection with elastic band
2. HCG Injections and B12 shots now in stock at US Vitamin Injections Site
3. Evolution of an outbreak: Complications from contaminated steroid injections
4. Media advisory: Brain cell injections may quiet epileptic seizures
5. Cancer vaccines self-sabotage, channel immune attack to injection site
6. Numerical study suggests subsea injection of chemicals didnt prevent oil from rising to sea surface
7. Study suggests different organ-derived stem cell injections improve heart function
8. Protein injection points to muscular dystrophy treatment
9. Laser-powered needle promises pain-free injections
10. Study in mice discovers injection of heat-generating cells reduces belly fat
11. Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
Post Your Comments:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology: